Highest-materiality recent filing
Nu-Med Plus closes acquisition of six Canadian gold properties via Maritimes Gold Corp
Closing on Aug 20, 2026; issued 500,000 Series A Preferred shares to MegumaGold, convertible to up to 10M common shares (20 votes each).
Nu-Med Plus completes acquisition of Avid Gold; Fred Tejada gains voting control
Acquired 100% of Avid Gold Ltd for 4,500,000 Series A Preferred shares and assumption of $100,000 note.
Nu-Med Plus to acquire Avid Gold Ltd and six gold properties in Canada via share exchange
Acquires 100% of Avid Gold Ltd for 4,500,000 Series A Preferred shares and assumption of $100,000 debt.
YourSpace terminated share exchange agreement on Oct 28, 2024, failing to provide audited 2023 financials.
Nu-Med Plus completes acquisition of YourSpace America, new CEO and majority control shift
Nu-Med Plus acquires YourSpace America via share exchange; YSA becomes wholly owned subsidiary as of April 28, 2024.
Nu-Med Plus to merge with YourSpace America; YSA's Colvin to become CEO with majority voting control
4,500,000 Series A Preferred shares (20:1 voting, convertible into 20 common each) issued to YSA shareholders at closing.
Nu-Med Plus enters non-binding LOI to merge with YourSpace America
LOI signed May 15, 2023; YourSpace America (YSA) to merge into Nu-Med Plus.
Nu-Med Plus dismisses auditor Sadler, Gibb & Associates, engages Fruci & Associates
Dismissed Sadler, Gibb & Associates on Feb 17, 2023; no disagreements on accounting principles or audit scope.
Nu-Med Plus issues $100K convertible note to Your Space Inc., due Dec 31, 2023
Issued 5% Convertible Promissory Note for $100,000 to Your Space, Inc. on Nov 18, 2022.
Nu-Med Plus issues $100K convertible promissory note to Your Space, Inc.
Issued 5% convertible promissory note for $100,000 to Your Space, Inc., due December 31, 2023.
Nu-Med Plus appoints Jeffrey L. Robins to Board of Directors
On October 18, 2022, Board unanimously appointed Jeffrey L. Robins as an additional member.
CEO Jeffrey Robins resigns; William Hayde appointed as CEO and Chairman
Jeffrey L. Robins resigned as President, CEO, Director and Chairman on Sept 12, 2022; Dr. Brett J. Earl resigned as director.
Nu-Med Plus announces resignation of three officers/directors; Dr. Morrison moves to advisory board
Thomas Tate resigned as VP of Scientific Development and director, effective Dec 31, 2021.
On October 28, 2024, the Board of Directors appointed Mr. William Hayde, who is the Chairman of the Board, to serve as President/Chief Executive Officer of Nu-Med.
Mr. Colvin submitted his resignation from the positions to which he had been appointed.
Following the appointment of Mr. Colvin as President and Chief Executive Officer, the Company’s former President and CEO William Hayde was appointed to serve as the Company’s Executive Chairman of the Board.
the Board of Directors of the Company appointed William R. “Russ” Colvin as the Company’s President, Chief Executive Officer, and Director of the Company.
On October 18, 2022, the Board of Directors recognized the need for an additional member of the Board of Directors, and unanimously consented to appoint Jeffrey L. Robins to the Board of Director.
On September 12, 2022, Jeffrey L. Robins resigned as President, Chief Executive Officer, Director and Chairman of the Board
and Dr. Brett J. Earl resigned as a director.
The Corporation has appointed Mr. William Hayde as the President, Chief Executive Officer, Director and Chairman of the Board.
On December 31, 2021, Thomas Tate resigned as Vice President of Scientific Development and a director; William Moon resigned as Vice President of Technology and a director; and Dr. Craig Morrison resigned as Vice President of Research and a director.
Dr. Craig Morrison resigned as Vice President of Research and a director. Dr. Morrison is moving to a position on our Medical Advisory Board.
On December 31, 2021, Thomas Tate resigned as Vice President of Scientific Development and a director; William Moon resigned as Vice President of Technology and a director; and Dr. Craig Morrison resigned as Vice President of Research and a director.
Max materiality 0.90 · Median 0.60 · Most common event m_and_a